Arbutus Biopharma

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Walmart's Thanksgiving Day Shutdown Could Affect New York Shoppers

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ABUS

AVAV

FTNT

KEYS

TCOM

Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday

Moderna

Biotech

Large Cap

Health Care

Legal

General

ALNY

MRNA

Alnylam Pharmaceuticals has conceded that Moderna&#39;s products do not infringe on its patents, as a court ruling determined. Both companies have agreed to dismiss the case without prejudice for possible future actions.

Alnylam&#39;s Concedes Its Patent Infringement Case Against Moderna&#39;s COVID-19 Vaccine

BZ_briefs

Movers

Delaware Judge favors Arbutus and Genevant Sciences in their patent dispute with Moderna over COVID-19 vaccine technology.

Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma Corp

Earnings

Press Releases

Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Arbutus to Present at Jefferies London Healthcare Conference

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Arbutus Provides 2025 Corporate and Financial Update

Management

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Comments

Arbutus Biopharma

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga